A clinical trial
has explored the use of preoperative misoprostol in reducing blood loss during fibroid removal surgery.
Fibroids are non-cancerous growths that develop in or around the womb (uterus). The growths are made up of muscle and fibrous tissue and vary in size. They're sometimes known as uterine myomas or leiomyomas. These fibroids can cause many symptoms such as abdominal pain, heavy bleeding between or during your periods, pain during intercourse, and trouble conceiving.
Myomectomy is a surgical procedure that involves the removal of fibroids from the uterus. It is a common treatment option for women who have symptomatic fibroids. However, the surgery can be challenging due to the potential for excessive bleeding, which can lead to complications. Doctors have been searching for treatment options to reduce this blood loss and have come up with several potential drugs including misoprostol.
Misoprostol is a medication that is commonly used to induce labor or to help with medical abortions. It works by causing the uterus to contract, which can lead to bleeding.
A recent clinical study explored the use of misoprostol to reduce bleeding during myomectomy surgery. The study was called POMMS, which stands for Pre-operative Misoprostol in Myomectomy Surgery.
The clinical study involved women above the age of 18 years from a tertiary care hospital in Australia who were due to undergo myomectomy surgery. Half of the women were given 400 mg of misoprostol before the surgery, while the other half received a placebo. The researchers then compared the amount of bleeding during the surgery between the two groups.
The results of the clinical trial showed that the average blood loss in the misoprostol group was 306 ml. On the other hand, the average blood loss in the placebo group was 325 ml. Additionally, the clinical study demonstrated that blood loss was correlated to the size of the fibroids. For each 1 ml increase in fibroid volume, there is an increase in blood loss by 0.26 ml.
These results indicate that the blood loss was not significantly different between the two groups. This signifies that misoprostol was not effective in reducing blood loss during fibroid removal surgery.
Reducing bleeding during myomectomy surgery is important because excessive bleeding can lead to complications such as anemia, the need for blood transfusions, and a longer recovery time. By reducing bleeding during the surgery, patients may have a shorter recovery time and experience fewer complications.
In conclusion, the POMMS clinical trial found that pre-operative misoprostol was not an effective drug to reduce bleeding during myomectomy surgery. This finding could have significant implications for women who undergo this procedure, as it indicates that misoprostol may not be beneficial.